Exelixis
EXEL
#1341
Rank
HK$125.94 B
Marketcap
HK$516.14
Share price
-3.60%
Change (1 day)
57.31%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): HK$27.08

According to Exelixis's latest financial reports the company's current EPS (TTM) is HK$27.13. In 2025 the company made an earnings per share (EPS) of HK$22.66.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$27.0819.5%
2025HK$22.66
2023HK$5.1214.61%
2022HK$4.47-22.97%
2021HK$5.80100%
2020HK$2.90-65.09%
2019HK$8.31-53.91%
2018HK$18.03333.96%
2017HK$4.16-260.61%
2016-HK$2.59-58.75%
2015-HK$6.27-42.45%
2014-HK$10.905.3%
2013-HK$10.35

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
HK$52.37 93.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$5.57-79.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$136.27 402.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$15.53-42.76%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$7.79-71.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$35.44 30.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
HK$22.56-16.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-HK$111.49-510.98%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-HK$6.59-124.28%๐Ÿ‡บ๐Ÿ‡ธ USA